Granules India — 360° view

Granules India, a company in the Pharmaceuticals industry, reported revenue of ₹1,560 crore and net profit of ₹182 crore for the September 2026 quarter.

Granules India (NSE: GRANULES) closed at ₹822.65 on 20 Nov 2026, up 49.4% over the past year. Its market capitalisation is ₹22,440 crore and it trades at 32.0 times earnings.

Share price
₹822.65 (20 Nov 2026)
Market cap
₹22,440 Cr (20 Nov 2026)
P/E
32.00 (20 Nov 2026)
Revenue
₹1,560 Cr (September 2026 quarter)
Net profit
₹182 Cr (September 2026 quarter)
ROCE
15.5% (FY26)
ROE
13.8% (FY26)
Book value
₹241 (FY26)
Dividend yield
0.21% (last 12 months to 20 Nov 2026)
52-week high / low
₹923.65 / ₹529.85 (20 Nov 2026)
1-year return
49.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GRANULES

Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.